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Background. The availability of large collections of microarray datasets (compendia), or knowledge about grouping of genes
into pathways (gene sets), is typically not exploited when training predictors of disease outcome. These can be useful since
a compendium increases the number of samples, while gene sets reduce the size of the feature space. This should be favorable
from a machine learning perspective and result in more robust predictors. Methodology. We extracted modules of regulated
genes from gene sets, and compendia. Through supervised analysis, we constructed predictors which employ modules
predictive of breast cancer outcome. To validate these predictors we applied them to independent data, from the same
institution (intra-dataset), and other institutions (inter-dataset). Conclusions. We show that modules derived from single
breast cancer datasets achieve better performance on the validation data compared to gene-based predictors. We also show
that there is a trend in compendium specificity and predictive performance: modules derived from a single breast cancer
dataset, and a breast cancer specific compendium perform better compared to those derived from a human cancer
compendium. Additionally, the module-based predictor provides a much richer insight into the underlying biology. Frequently
selected gene sets are associated with processes such as cell cycle, E2F regulation, DNA damage response, proteasome and
glycolysis. We analyzed two modules related to cell cycle, and the OCT1 transcription factor, respectively. On an individual
basis, these modules provide a significant separation in survival subgroups on the training and independent validation data.
Citation: van Vliet MH, Klijn CN, Wessels LFA, Reinders MJT (2007) Module-Based Outcome Prediction Using Breast Cancer Compendia. PLoS
ONE 2(10): e1047. doi:10.1371/journal.pone.0001047
INTRODUCTION
Unraveling the structure of complex biological processes from
genomic data sources has been a focal point in bioinformatics
research. Thus far, supervised analysis of microarray data has been
performed in a data-driven fashion [1–4]. These studies have
reported and tested prognostic markers, sets of genes, which are
predictive of treatment response and outcome.
One of the mainissuesindata-driven approachesisthesmallratio
of samples relative to the number of genes for a particular study,
causing small sample size related problems. This problem can be
addressed by reducing the number of features (input variables) or
increasing the number of samples. The latter approach was pursued
by combining two or even more datasets and then deriving
prognostic markers from the resulting dataset [5–8]. Employing
more samples results in, for instance, better estimates of gene
variances and improves estimates of the t-statistic [9]. This approach
was also followed by Segal et al. [10] and Tanay et al. [11] who
constructed microarray gene expression compendia (collections of
microarray data sets spanning a diversity of phenotypes).
The supervised analyses performed on compendia are data-
driven and currently still employing single genes as input features.
As an alternative, knowledge of functional groupings of genes into,
for example pathways, can be employed to define meta-features,
called modules. Such meta-features have two important advan-
tages. Firstly, a relevant module can be directly linked to the
biological processes that underly the observed outcome. Secondly,
moving from a gene-based to a module-based representation
reduces the number of input variables, which alleviates the small
sample size problem.
Segal et al. [10] proposed a framework for the unsupervised
knowledge-driven analysis of expression data. Within this
framework, modules are extracted based on relevant gene sets
from a compendium of microarray data. We follow that approach,
and extend the framework to include a supervised classification
analysis based on the extracted modules and the available clinical
data. In addition, we introduce cancer-specific compendia, as an
intermediate step between a single dataset and a complete human
cancer compendium. Employing the supervised framework, we
evaluate the predictive performance of classifiers derived from
cancer-specific datasets, a cancer specific compendium, and
a human cancer compendium. In addition, we wanted to
investigate the capacity of these classifiers to generalize beyond
the dataset on which they were trained. Therefore, we set up an
experiment in which we validated our classifier on independent
data from the same institution (intra-dataset validation), a combi-
nation of institutions (cross-dataset validation), and by validating
on data from different institutions (inter-dataset validation).
Finally, since we adopted the module extraction of Segal et al.
[10], the optimized set of modules that is selected by the supervised
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results. That is, the modules can be related to the original gene
sets, and thus, to cellular processes, giving more insight into the
mechanisms causing the outcome differences.
METHODS
Our method extends the unsupervised knowledge-driven frame-
work proposed by Segal et al. [10] to the supervised classification
domain. This extension allows the identification of module-based
prognostic markers, rather than gene-based markers. The entire
outline of our methodology is presented in Figure 1.
Input: Compendium
The usual approach is to analyse a single microarray dataset in
isolation. To find cancer related modules, Segal et al. [10] proposed
to take multiple datasets into account that are all related to human
cancer types (Figure 1, Step 1). With this global human cancer
compendium (HCC), they formed modules of genes that regulate
cancer in a general way. We focus on breast cancer, for which
various datasets are available. We propose to construct cancer
specific compendia, in our case breast cancer compendia (BCC), as
an intermediate step between a single breast cancer dataset (BC) and
a complete human cancer compendium (HCC), see Figure 2 and
Table 1. These cancer specific compendia will reduce the small
sample size problem, but at the same time should ensure coherence
in underlying phenotype compared to the more global human
cancer compendium. Figure 2 shows an example of how datasets
from different institutions have been grouped into compendia.
In our analyses we have also used the HCC that was published
by Segal et al. [10]. This compendium contains data from various
cancer types and has a total of 1973 arrays, for which 14143 genes
are present. The compendium already contained data from three
previous breast cancer studies, in total 152 arrays: 26 arrays from
the first study by Perou et al. [12], 41 arrays from the second study
by Perou et al. [13], and 85 arrays from Sorlie et al. [14].
The additional breast cancer microarray datasets that we have
used, originate from previously published research [2–4]. The
Vijver dataset consists of 295 breast cancer patients, the Wang
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Figure 1. Workflow of the approach. We extended the analysis of compendia [10] to the supervised classification domain. Several microarray
datasets were collected to construct compendia at various levels of underlying phenotype diversity (1). Additionally, we gathered a collection of
biologically meaningful gene sets from available databases (2). Using the module extraction framework proposed by [10], we derived sets of modules
(3) from these compendia and gene sets. Using these modules we construct a module activity matrix (4), allowing modules rather than single genes
to be used as features. The predictive power of the different sets of modules is inspected within a classification context. Using a train/test protocol (5),
we estimated the generalization error of all sets of modules [17]. Succeedingly, we trained a final classifier (6), which was then validated on
independent data (7), and its performance assessed (8). Furthermore, the approach allows the final set of modules that were selected in the classifier
to be compared to the original gene sets (9), allowing the identification of biological processes underlying the development and progression of
cancer.
doi:10.1371/journal.pone.0001047.g001
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Figure 2. Compendia of microarray data. Microarray datasets can be
grouped into compendia at various levels of underlying phenotypic
diversity. The pie-chart indicates datasets from various origins, sizes,
and cancer types, and the compendia are indicated by the outer rings.
The ’Inter1’ training-validation configuration is depicted in this figure
([4] as training, and [3] as validation). This is one of the six
configurations employed (See Table 1 for details).
doi:10.1371/journal.pone.0001047.g002
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records. To be able to use these datasets in conjunction with the
HCC, we mapped all the available probes to the same set of
Entrez ids in the HCC. Furthermore, after mean-normalisation,
we discretized each dataset separately into three levels: induced (1),
basal (0), and repressed (21), taking into account the skewing and
variance in each of the datasets (Discretization was applied,
because the module extraction procedure that Segal et al. [10]
proposed, requires a discrete input.).
Outcome data (time to metastasis) was available for all patients
in the Vijver and Wang datasets. For classification, the poor
outcome group was defined as all patients with time to metastasis
less than five years, and the good outcome group as those with
time to metastasis greater than or equal to five years. Censored
patients in the poor group were not taken into account when
training and assessing a classifier. On the other hand, censored
patients in the good group were included in both the training and
validation [15].
Input: Gene Set Collection
We collected 2682 gene sets from several biological databases and
resources (Figure 1, Step 2), including some additional databases
that were not included in the collection of gene sets used by Segal
et al. [10], see Figure 3. In the original analysis presented by Segal
et al. [10], approximately half of the gene sets were obtained by
performing hierarchical clustering on the expression data. We
chose to omit any hierarchical clusters in the collection of gene
sets, as the inclusion of hierarchical clusters would introduce an
additional data-driven bias. As a result, our analysis is more
knowledge-driven when compared to the original study.
Unsupervised Analysis
To extract modules from compendia of microarrays, we largely
followed the knowledge-driven approach proposed by Segal et al.
[10] (Figure 1, Step 3). In short, this unsupervised method finds
modules in (compendia of) discretized microarray data. A module is
defined as a subset of genes with correlated expression across a set of
arrays, and is constructed by combining (parts of) gene sets based on
discretized gene expression data. The module extraction process can
be seeded by biologically relevant gene sets (extracted from e.g. GO
and KEGG), thus incorporating a knowledge-driven component in
the analysis. An in depth description of the procedure is given in the
supplementary Text S1, and supplementary Figure S1.
Following the extraction of the modules, a module activity
matrix is constructed for the training data as well as the validation
data (Figure 1, Step 4). The module activity matrix represents the
behavior of the group of genes in a module by a discrete variable.
The conversion from gene expression to module activity is done
per array, per module. For the induced and repressed genes
separately, we test whether the overlap of induced or repressed
genes on the array with the module is significant, compared to
Table 1. Experimental setup.
......................................................................
Features nn opt Training Validation Validation
Intra/Cross-lab Validation Intra1 Cross1
Genes 10962 48 V1 V2 V2+W2
BC (V1) 747 44 V1 V2 V2+W2
BCC (V1+W1+So) 911 66 V1 V2 V2+W2
HCC (Se) 1163 111 V1 V2 V2+W2
S456 (Se) 456 80 V1 V2 V2+W2
Inter-lab Validation Inter1
Genes 10962 21 V W
BC (V) 896 55 V W
BCC (V+So) 934 137 V W
HCC (Se) 1163 104 V W
S456 (Se) 456 42 V W
Intra/Cross-lab Validation Intra2 Cross2
Genes 10962 101 W1 W2 V2+W2
BC (W1) 576 59 W1 W2 V2+W2
BCC (V1+W1+So) 911 103 W1 W2 V2+W2
HCC (Se) 1163 71 W1 W2 V2+W2
S456 (Se) 456 67 W1 W2 V2+W2
Inter-lab Validation Inter2
Genes 10962 58 W V
BC (W) 704 17 W V
BCC (W+So) 762 33 W V
HCC (Se) 1163 78 W V
S456 (Se) 456 10 W V
Our experimental setup allows a validation of the classifiers on data from the
same institution (Intra1 and Intra2), data from the same and another institution
(Cross1 and Cross2), and data from another institution (Inter1 and Inter2). In all
cases the training and validation sets are non-overlapping, and thus
independent. Moreover, the validation data was not used in the first step where
the unsupervised approach is used to extract modules. In each of the validation
schemes we included a gene-based classifier (Genes), and several module-
based classifiers (BC, BCC, HCC, and S456). For each of the module-based
classifiers we indicate the datasets from which the modules were extracted
(Features column), along with the number of features (n), and the optimal
number of modules/genes output from the train/test protocol (nopt). The
Training column indicates the dataset on which the train/test protocol was
used, and the Validation column indicates the datasets used for validation of
the classifiers. All datasets are abbreviated as: V: [4], W: [3], So: [2], and Se: [10].
When we split a dataset in two equal independent parts we indicate the
training (1) and validation (2) parts by subscripts.
doi:10.1371/journal.pone.0001047.t001
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Figure 3. Pie chart indicating the origin of the gene sets. A total of
2682 gene sets were collected. The GO, KEGG, GenMapp, and Tissue
specific gene sets were taken from the study by Segal et al. [10]. The
Reactome pathways were downloaded from the Reactome website [23],
and the MSDB gene sets were taken from the molecular signature
database [24].
doi:10.1371/journal.pone.0001047.g003
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distribution to calculate a p-value for the significance of the
overlap. Following FDR correction [16] (significance thresh-
old=0.05) one of the following four situations occur:
N Neither p-value is significant: the module activity is basal (i.e. 0)
N Only the induction p-value is significant: the module is induced
(i.e. 1)
N Only the repression p-value is significant: the module is
repressed (i.e. 21)
N Both p-values are significant: the module activity is basal (i.e. 0)
Figure 4 presents an example of a set of microarrays and
modules that are converted to a module activity matrix.
For each of the validation schemes (Table 1) we constructed
several module-based classifiers (BC, BCC, HCC, S456) based on
modules extracted from the datasets indicated in the Features
column of Table 1.
Supervised Analysis
Supervised classification provides a means to identify modules with
activities that are significantly associated with some relevant
outcome variable, such as, metastasis-free survival in breast cancer
(Figure 1, Step 5). To obtain an unbiased estimate of the
generalization error of the different sets of modules, we used
a double-loop cross validation procedure [17].
In our experiment, we focused on differences between the sets of
modules and we omitted an extensive evaluation of a range of
different classifier types. Since all features are discrete, we used
forward filtering as module selector, the mutual information as
criterion to evaluate the individual modules (using maximally 200
modules), and a simple Bayes classifier [18]. For the discretized
gene-expression data we used the same setup as for the module-
based approach.
Following the Train/Test procedure, we trained a final classifier
(Figure 1, Step 6). This classifier was trained using the top ranked
features, that were estimated in the train/test protocol. The final
classifier was validated on an independent dataset (Figure 1, Step
7), which had not been employed in any of the training steps
(Figure 1, Steps 2–6).
To assess the performance of the classifiers on the independent
validation dataset, we constructed an ROC curve (Figure 1, Step 8).
To compare the performance of various feature types we adopted
the area under the curve (AUC) as a performance measure.
Finally, a feedback step relates the modules selected in the
classifier to the original gene sets (Figure 1, Step 9). This allows
direct insight into the underlying mechanisms, compared to the
annotation lookup of single genes in terms of functional groups in
data-driven approaches.
Experimental Setup
We wanted to investigate the capacity of our classifiers to
generalize beyond the dataset that they were trained on.
Therefore, we designed our experiments such that three different
validation schemes were possible. In all cases the training and
validation sets are non-overlapping (independent), i.e. no samples
that were used during module extraction/training are employed in
the validation. The following three scenarios were considered:
training and validation on data from 1) the same institution
(denoted as intra-lab validation); 2) a combination of the same and
other institutions (cross-lab validation); and 3) separate institutions
(inter-lab validation). Since we had equivalent outcome data for
the Vijver and Wang datasets, we mirrored the role of both so that
we ended up with a total of six experiments, as shown in Table 1.
RESULTS AND DISCUSSION
Extracting modules from the compendia
For each of the compendia we derived a set of modules using the
discretized gene expression data as well as the 2682 gene sets as
input. The number of modules that were found are listed in
Table 1. The number of modules found ranged from 576 to 1163,
which is a significant reduction in the number of features from the
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Figure 4. Converting gene expression data into module activity data. For a given gene expression dataset, and a set of modules we assessed the
statistical significance of the overlap of induced/repressed genes with the modules using the hypergeometric distribution. This leads to two p-values
for each array/module pair. These p-values are combined into a single discrete module activity score.
doi:10.1371/journal.pone.0001047.g004
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published 456 modules [10] in the current investigation (S456).
These differ from the HCC modules, as they are constructed based
on gene sets derived by hierarchical clustering.
Classification performances
The classification performances of the experiments listed in
Table 1, are compared based on the AUCs obtained on the
validation data. For each of the six experiments (Intra1, Cross1,
Inter1, Intra2, Cross2, Inter2) the results obtained with each
feature type (BC, BCC, HCC, S456, Genes) were ranked based on
the AUC. Figure 5 shows a boxplot of the ranks obtained for each
of the feature types. A table containing all individual AUC values
and ranks is presented in the supplementary information (Table
S1). The median rank of the BC features is the lowest of all the
feature sets, the BCC median rank is slightly worse, but still better
than the HCC, S456, and Genes features which perform the
worst.
To assess the statistical significance of the observed differences
between the median ranks, we applied a one-sided Wilcoxon rank
sum test to all pair-wise combinations of feature types. The
obtained p-values are depicted in the left panel in Figure 6. We
also employed the Wilcoxon rank sum test to perform pair-wise
comparisons between the feature types derived from breast cancer
compendia (BC+BCC), features types derived from human cancer
compendia (HCC+S456) and Genes. The results are depicted in
the right panel of Figure 6.
Fromthe left panel inFigure 6 we can conclude that, although the
BCC modules have a lower median rank compared to the HCC
modules, S456 modules, and Genes, there is not enough statistical
evidence (at the 0.05 level) to support the claim that the BCC
modules outperform the HCC modules, S456 modules, or the
Genes. Since the BCC modules are derived from a larger collection
ofdatathantheBCmodules,wewouldhaveexpectedaperformance
that is at least equal and possibly even better than the BC modules.
Since breast cancer is known to be a heterogeneous disease, we
hypothesize that differences in the subtype composition of the
datasets cause the poorer performance of the BCC modules.
From the right panel in Figure 6, we can, however, conclude
that the BC and BCC modules jointly perform better than the
HCC, and S456 modules (p=0.006). This indicates that a human
cancer compendium lacks specificity with respect to a breast
cancer compendium. We can therefore conclude that for breast
cancer specific prediction, a cancer specific compendium is more
suitable compared to a more global human cancer compendium.
As shown by Segal et al.[10] the HCC and S456 modules may still
be relevant for identifying differences between cancer types.
The pairwise comparisons (left panel in Figure 6) indicate that the
median rank of the BC modules is better than each of the other
feature types (all p,0.05). Moreover, gene-based classifiers show
a very large variability in comparison to BC module-based classifiers
(see Figure 5). One possible explanation for this observation is that
the conversion of gene expression data to module activity data may,
in fact, function as a form of regularization which removes noise.
1
1.5
2
2.5
3
3.5
4
4.5
5
R
a
n
k
s
Features
B
C
B
C
C
H
C
C
S
4
5
6
G
e
n
e
s
Figure 5. Boxplot showing ranked AUC results. Boxplot showing the
median ranks of the performance of each of the five feature types
across the six experiments (see Table 1). In each of the six experiments
the features were ranked based on the AUC obtained on the
independent validation set (1 best, 5 worst).
doi:10.1371/journal.pone.0001047.g005
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Figure 6. Pairwise comparison of the five feature types. Each cell (row=i, column=j) depicts the the p-value obtained by performing a one-sided
Wilcoxon rank sum test with as alternative hypothesis that the median rank of type i is lower than type j, based on the AUCs achieved for each of the
six experiments. The plot on the left shows individual comparisons, the plot on the right includes comparisons of groups of features. Cell-shading
reflects the p-values.
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a given classifier.Wehypothesizethatthefactthat genesina module
are roughly associated with the same biological process, ensures an
optimal degree of regularization.
For a given classifier to serve as a prognostic index in clinical
practice, a suitable operating point on its associated ROC curve
needs to be selected. For outcome prediction in breast cancer, the
True Positive Rate (TPR) is typically set at a desired threshold,
and based on the ROC curve, the corresponding False Positive
Rate (FPR) possible is determined. Therefore, we have re-
evaluated the AUC scores by integrating over the TPR interval
ranging from 0.5 to 1. This interval was chosen since it reflects
a clinically more relevant range than the complete TPR range
([0,1]). All results are reported in the supplementary information
(Table S2, Figure S2 and Figure S3). Consistent with earlier
results, the BC modules perform significantly better compared to
all other feature types. In addition, the BCC modules now have
a significantly lower median rank compared to the HCC and S456
modules (p=0.05, and p=0.01). This strengthens our conclusion
that the BC modules perform better than the other feature types,
and that a breast cancer specific compendium performs better
compared to a human cancer compendium, especially when
considering a clinically relevant setting.
Interpretability of Gene and Module-based
signatures
All classifiers output a signature of relevant features, that is
predictive for survival. To better understand the biological
processes associated with disease outcome in breast cancer, the
signatures are further investigated. For gene-based features, the
overlap with known pathways is employed to attach biological
meaning to an obtained signature. Module-based classifiers, on the
other hand, return a set of predictive modules rather than single
genes. Each of these individual modules may provide links to
relevant biological processes. Moreover, since modules are
extracted from the data by combining (parts of) gene sets, these
may link additional genes to known pathways, which are relevant
to disease progression in breast cancer.
To explore the association of the signatures to biological
processes, we analyzed a gene-based and BC module-based
signature. We chose to compare the gene-based signature and BC
module-based signature from Inter1 (Table 1), since they were
derived from the same dataset. These signatures consist of 21
genes, and 55 modules (Dataset S1), respectively.
For every module in the module-based signature, as well as the
21 single-gene signature, we computed the enrichment for each of
the 2682 gene sets employing the hypergeometric distribution. For
the gene-based signature no gene sets were significantly enriched
(p,0.05 after Bonferroni correction), whereas 319 gene sets were
significantly enriched in at least 1 of the 55 modules in the module-
based signature (p,0.05 after Bonferroni correction). The
complete matrices of raw p-values are depicted in supplementary
information (Text S1, and Figure S4).
Many of the 319 gene sets are associated with similar biological
processes within the context of the 55 module signature (i.e. they
have similar enrichment profiles across the 55 modules).
Therefore, we clustered the gene sets based on enrichment scores
into seven distinct clusters employing complete linkage, hierarchi-
cal clustering with Euclidean distance as dissimilarity measure.
The common biological themes associated with the gene sets in
each of the resulting seven clusters are listed on the left in Figure 7.
Based on the complete table of enrichment p-values (Supple-
mentary Figure S4), it is evident that there are clusters of modules
that also show a similar enrichment pattern across the gene sets.
Therefore, we clustered the modules into seven distinct groups, as
depicted by the dendrogram at the top in supplementary Figure
S4. These clusters were labeled Module groups 1 to 7, as indicated
at the bottom in Figure 7.
The main table in Figure 7 shows the aggregated enrichment p-
values. More specifically, cell (i, j) depicts the median enrichment
p-value for all modules in module group j with respect to all gene
sets in gene set group i. The column vector on the right shows the
median enrichment scores for the groups of gene sets with respect
to the single gene signature.
Figure 7 shows several strong links of the module-based
signature to biological processes. Five out of the seven groups of
modules can be linked to biological processes that are known to be
involved in cancer progression (Cell Cycle, DNA Damage, E2F
transcription factors, and Proteasome). Most of these have been
previously related to breast cancer [19]. It is interesting to note
that glycolysis has only recently been identified as a key factor in
tumor progression [20].
A detailed analysis of two modules
Based on the module activity representation, the arrays in a dataset
can be separated into 3 groups: arrays where the module is
activated, repressed or showing basal activity. Using this
separation, we present the Kaplan-Meier curves for two modules
from the module-based signature, on the training data [4], as well
as on the independent validation data [3], see Figures 8 and 9.
Figure 8 shows a module (from Module group 2) that has
a highly significant overlap with Cell Cycle related gene sets
(enrichment of the top gene set: p,10
251), see Figure 7. This
module is significantly associated with disease progression on both
the datasets from Vijver et al. [4] (p,0.0001) and Wang et al. [3]
(p=0.0127). Deregulation of the cell cycle has been identified as
one of the hallmarks of cancer [19]. More importantly, an
increased activity of the cell cycle has been linked to more
aggressive tumors. This is in accordance with our observation for
this module, which shows that an induced module activity is linked
to the subgroup with the worst outcome. Conversely, a repressed
module activity shows the best outcome.
Figure 9 shows a module (from Module group 4) that has
a significant enrichment for OCT1 transcription factor related
gene sets (enrichment of the top gene set: p,10
212). The Kaplan-
Meier curves show a significant separation between the induced,
basal, and repressed module activities on both the Vijver et al. [4]
data (p,0.0001), and the Wang et al. [3] data (p=0.0098). In
breast cancer, the OCT1 transcription factor is known to be often
overexpressed [21] relative to normal breast tissue, but its exact
role in the tumorigenic process has remained unclear. Addition-
ally, OCT1 has been identified as a transcriptional repressor [22].
We show that the concerted repression of downstream targets of
the OCT1 transcription factor relates to a poor outcome group.
On the other hand, an induced module activity relates to
a subgroup with significantly better outcome. Thus, this module
can be identified as a potential tumor suppressor module.
Conclusion
By extending an existing unsupervised knowledge-driven frame-
work to the supervised classification domain, we were able to
investigate the effects of including knowledge from previous gene
expression studies (through compendia) as well as known cellular
processes (through gene sets) on the accuracy of outcome
prediction in breast cancer. Our analysis included a validation of
the classifiers on independent data, which allowed for an objective
Modules in Outcome Prediction
PLoS ONE | www.plosone.org 6 October 2007 | Issue 10 | e1047evaluation of the actual generalization behavior of the gene-based
and module-based classifiers in a clinically relevant setting.
Classifiers based on genes had a very large variance, compared to
the BC module-based classifier. We hypothesize that the conversion
of gene expression data to module activity functions as a regulariza-
tion step, where the extent of the regularization is controlled by the
specificity of the modules, resulting in more stable classifiers.
Overall, a trend emerges in the performance versus compen-
dium specificity. Modules from the most specific single dataset
showed the best performance-significantly outperforming all other
classifiers. These were closely followed by modules extracted from
a breast cancer specific compendium, which performed signifi-
cantly better than modules from the human cancer compendium
when evaluated across a clinically relevant TPR range. Finally,
modules from the human cancer compendium showed the weakest
performance. This indicates that it is preferable to employ
a compendium specific to the cancer type under study. Moreover,
the heterogeneity between different institutions tends to be more
detrimental than the gain in sample size when a breast cancer
specific compendium is constructed.
A module-based approach to classification provides a signature
of predictive modules, as opposed to a gene-based signature.
Interpretation of a gene-based signature is usually limited to
a mapping of the genes in the signature to functional categories.
However, for the approach outlined here, it holds that the modules
were constructed from biologically meaningful gene sets, and
therefore these can be linked directly to the underlying biological
processes. We illustrated this advantage by providing a meta-
representation of the modules in one of the module-based
classifiers, which reveals molecular processes, such as cell cycle,
DNA damage, glycolysis, and proteasome, known to be involved
in breast cancer. The gene-based signature provided no significant
links at all. This gain in biological insight greatly favors the use of
a module-based classifier.
Our research includes an in-depth analysis of two modules that
were part of the module-based signature, which were related to
0.429 1.000 1.000 1.000 0.500 0.039 0.000
0.030 1.000 1.000 1.000 1.000 1.000 1.000
0.002 0.004 0.521 1.000 1.000 1.000 1.000
0.528 0.828 0.793 0.011 1.000 0.165 0.333
1.000 1.000 1.000 0.046 1.000 0.582 1.000
0.000 0.000 0.190 0.396 1.000 0.441 0.274
0.000 0.000 0.507 1.000 1.000 1.000 1.000
Clusters of modules with a similar enrichment pattern
M
o
d
u
l
e
 
g
r
o
u
p
 
1
 
(
1
1
)
M
o
d
u
l
e
 
g
r
o
u
p
 
2
 
(
1
3
)
M
o
d
u
l
e
 
g
r
o
u
p
 
3
 
(
2
)
M
o
d
u
l
e
 
g
r
o
u
p
 
4
 
(
2
0
)
M
o
d
u
l
e
 
g
r
o
u
p
 
5
 
(
4
)
M
o
d
u
l
e
 
g
r
o
u
p
 
6
 
(
2
)
M
o
d
u
l
e
 
g
r
o
u
p
 
7
 
(
3
)
1.000
0.387
0.336
1.000
1.000
0.283
0.119
G
e
n
e
 
S
i
g
n
a
t
u
r
e
Glycolysis
Proteasome / Mitotic Cell Cycle
DNA Damage / Cell Cycle Checkpoint
Transciption factor activity
Steroid Binding
Cell Cycle 
 E2F / Immune Response
 
 
0
0.2
0.4
0.6
0.8
1
C
l
u
s
t
e
r
s
 
o
f
 
g
e
n
e
 
s
e
t
s
 
w
i
t
h
 
a
 
s
i
m
i
l
a
r
 
e
n
r
i
c
h
m
e
n
t
p
a
t
t
e
r
n
 
t
h
a
t
 
p
o
i
n
t
 
t
o
 
a
 
c
o
m
m
o
n
 
t
h
e
m
e
A: Module-based Signature B: Gene-based signature
Figure 7. Comparison of a module-based signature (A) and a gene-based signature (B). The module-based signature from the Inter1 experiment
contains 55 modules, and the gene-based signature contains 21 genes (Table 1). For both signatures an enrichment score for their overlap with the
collection of 2682 gene sets was calculated based on the hypergeometric distribution. This resulted in a total of 319 gene sets that were enriched in
at least one module or in the gene-based signature (p,0.05 after Bonferroni correction), see supplemental figure S4. Several modules turned out to
have a similar pattern of enrichment across the gene sets. Additionally, gene sets that relate to a common theme turned out to have a similar
enrichment pattern across the modules. Therefore, we clustered the matrix of p-values in both dimensions (2-dimensional, hierarchical clustering,
complete linkage, Euclidean distance). The dendrograms at the top, and to the left indicate the clustering, where we chose to group either dimension
into seven distinct groups. The labels on the left indicate the most common biological theme, and the label on the bottom indicates the groups of
modules formed along with the number of modules in each group in brackets. The main table shows the median p-value for the enrichment of each
of the seven clusters of modules, across these seven groups of gene sets. Similarly, the table on the right shows the median p-values for the gene
signature. Shading of the cells reflects the p-values.
doi:10.1371/journal.pone.0001047.g007
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PLoS ONE | www.plosone.org 7 October 2007 | Issue 10 | e1047cell cycle, and the OCT1 transciption factor. By themselves, these
modules provide a significant separation in subgroups on the
training and independent validation data. The cell cycle related
module indicated that an induced module activity is linked to the
worst outcome. This confirms the well known relationship between
the cell cycle process and cancer in general. On the other hand,
the OCT1 related module revealed a novel relationship to breast
cancer outcome. Based on its module activity, this module could
be designated as a tumor repressor module. Neither of these
factors could be revealed from the gene-based signature.
Therefore, we conclude that module-based signatures provide
a much richer insight to the underlying biology compared to gene-
based signatures.
Research on outcome prediction not only contributes to the
development of reliable diagnostic tests, but also by improving our
understanding of the processes involved in carcinogenesis, and
specifically how these influence disease progression and therapy
response. From a practical perspective, diagnostic tests based on
small gene sets are preferred, and are also designed with this
objective in mind. However, such sets often fail to provide
significant biological insight into the disease. Our module-based
classifiers were not designed to employ a minimal number of
genes, and the large number of genes employed could be
a limitation to the direct application of these classifiers in a clinical
setting. However, in our study, the module-based classifier had
a significantly lower variance in performance than the gene based
classifier, a property which is clearly preferable in the clinical
setting. We clearly demonstrate that the module-based gene sets
provide a much richer feedback by revealing functional categories
associated with disease outcome. These insights could speed up the
development of anti-cancer drugs, since the identified processes
will help focus the search for viable drug targets. In conclusion,
while module-based classifiers are perhaps less practical for clinical
use due to the large gene sets being employed, their robustness and
the biological insights they provide will most likely result in both
short and long term clinical benefit.
SUPPORTING INFORMATION
Text S1 Module-based outcome prediction using breast cancer
compendia.
Found at: doi:10.1371/journal.pone.0001047.s001 (0.11 MB
DOC)
Figure S1 Methodology overview. Overview of the unsupervised
module extraction procedure, followed by a supervised investiga-
tion of the relation between module expression and conditions. In
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Figure 8. A cell cycle related module. A) Module activity data of a Cell Cycle related module (Module group 2 in Figure 7) that was extracted from
the Vijver [21] data (Inter1, Table 1). The top heatmap shows the binary condition label, and the discrete module activity data (rows), for all the Vijver
arrays (columns) [4]. Arrays are ordered according to the metastasis free survival time. The heatmap in the middle shows the discrete gene expression
data for the 55 genes (rows) in the module. On the left, a binary heatmap shows the 55 genes, along with the gene sets that show the most
significant overlap with this module. The gene sets are ranked based on their p-value for the overlap with the module (hypergeometric distribution),
we show the top 10 gene sets (p-values ranging from 10
251 to 10
225, all significant at p,0.05 after Bonferroni correction). On the right, two Kaplan-
Meier curves indicate the predictive power of this module when arrays with the same module activity are grouped. B) The Kaplan-Meier curves for the
three groups defined by the activity of this module on the Vijver [21] data (Inter1 training, Table 1). C) The Kaplan-Meier curves for the three groups
defined by the activity of this module on the independent [3] data (Inter1 test data, Table 1). The legend indicates the three groups and lists the
number of events and total number within the groups. P-values correspond to the logrank test.
doi:10.1371/journal.pone.0001047.g008
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PLoS ONE | www.plosone.org 8 October 2007 | Issue 10 | e1047this example no FDR correction was done, so as to retain a fair
amount of significantly expressed gene sets/modules.
Found at: doi:10.1371/journal.pone.0001047.s002 (1.16 MB EPS)
Figure S2 Boxplot showing ranked AAC results. In each of the
six experiments the features were ranked based on the AAC (TPR
range from 0.5 to 1) obtained on the independent validation set (1
best, 5 worst). This boxplot shows the median rank along with the
quartile ranges for each of the five features.
Found at: doi:10.1371/journal.pone.0001047.s003 (0.59 MB EPS)
Figure S3 Comparison of ranked AAC results. Two tables
showing a pairwise comparison of the five feature types. Each cell
(row=i, column=j) depicts the the p-value obtained by perform-
ing a one-sided Wilcoxon rank sum test with as null hypothesis
that the median rank of type i is lower than type j, based on the
AACs (TPR range from 0.5 to 1) achieved for each of the six
experiments. The plot on the left shows individual comparisons,
the plot on the right includes comparisons of groups of features.
Cell-shading reflects the p-values.
Found at: doi:10.1371/journal.pone.0001047.s004 (0.81 MB
EPS)
Figure S4 Comparison of a module-based signature (A) and
a gene-based signature (B). The module-based signature from the
Inter1 experiment contains 55 modules, and the gene-based
signature contains 21 genes (Table 1). For both signatures an
enrichment score for their overlap with the collection of 2682 gene
sets was calculated based on the hypergeometric distribution. This
resulted in a total of 319 gene sets that were enriched in at least
one module or in the gene-based signature (P,0.05 after
Bonferroni correction). Several modules turned out to have
a similar pattern of enrichment across the gene sets. Additionally,
gene sets that relate to a common theme turned out to have
a similar enrichment pattern across the modules. Therefore, we
clustered the matrix of p-values in both dimensions (2-dimension-
al, hierarchical clustering, complete linkage, Euclidean distance).
The dendrograms at the top, and to the left indicate the clustering,
where we chose to group either dimension into seven distinct
groups. The labels on the right indicate the individual gene set
labels, and the label on the bottom indicates the groups of modules
formed along with the number of modules in each group in
brackets. The main table shows the median p-value for the
enrichment of each of the seven clusters of modules, across these
seven groups of gene sets. Similarly, the table on the right shows
the median p-values for the gene signature. Shading of the cells
reflects the p-values.
Found at: doi:10.1371/journal.pone.0001047.s005 (4.12 MB EPS)
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Figure 9. An Oct1 related module. A) Module activity data of an OCT1 transcription factor related module (Module group 4 in Figure 7) that was
extracted from the Vijver [21] data (Inter1, Table 1). The top heatmap shows the binary condition label, and the discrete module activity data (rows),
for all the Vijver arrays (columns) [4]. Arrays are ordered according to the metastasis free survival time. The heatmap in the middle shows the discrete
gene expression data for the 47 genes (rows) in the module. On the left, a binary heatmap shows the 47 genes, along with the gene sets that show
the most significant overlap with this module. The gene sets are ranked based on their p-value for the overlap with the module (hypergeometric
distribution), we show the top 10 gene sets (p-values ranging from 10
213 to 10
27, all significant at p,0.05 after Bonferroni correction). On the right,
two Kaplan-Meier curves indicate the predictive power of this module when arrays with the same module activity are grouped. B) The Kaplan-Meier
curves for the three groups defined by the activity of this module on the Vijver [21] data (Inter1 training, Table 1). C) The Kaplan-Meier curves for the
three groups defined by the activity of this module on the independent [3] data (Inter1 test data, Table 1). The legend indicates the three groups and
lists the number of events and total number within the groups. P-values correspond to the logrank test.
doi:10.1371/journal.pone.0001047.g009
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